198 related articles for article (PubMed ID: 19088261)
21. Tocilizumab in refractory adult-onset Still's disease with aseptic meningitis--efficacy of interleukin-6 blockade and review of the literature.
Sabnis GR; Gokhale YA; Kulkarni UP
Semin Arthritis Rheum; 2011 Feb; 40(4):365-8. PubMed ID: 20621335
[TBL] [Abstract][Full Text] [Related]
22. Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still's disease.
Naniwa T; Ito R; Watanabe M; Hayami Y; Maeda S; Sasaki K; Iwagaitsu S
Clin Rheumatol; 2013 Mar; 32 Suppl 1():S103-6. PubMed ID: 20842515
[TBL] [Abstract][Full Text] [Related]
23. Canakinumab in a case of adult onset still's disease: efficacy only on systemic manifestations.
Lo Gullo A; Caruso A; Pipitone N; Macchioni P; Pazzola G; Salvarani C
Joint Bone Spine; 2014 Jul; 81(4):376-7. PubMed ID: 24462130
[No Abstract] [Full Text] [Related]
24. [Refractory adult-onset Still's disease].
Fain O; Rouaghe S; Stirnemann J
Rev Prat; 2010 Mar; 60(3):314. PubMed ID: 20402117
[No Abstract] [Full Text] [Related]
25. Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still's disease: the first case report.
Benucci M; Li GF; Del Rosso A; Manfredi M
Clin Exp Rheumatol; 2005; 23(5):733. PubMed ID: 16173267
[No Abstract] [Full Text] [Related]
26. Successful treatment of refractory adult onset Still's disease with rituximab.
Ahmadi-Simab K; Lamprecht P; Jankowiak C; Gross WL
Ann Rheum Dis; 2006 Aug; 65(8):1117-8. PubMed ID: 16837497
[No Abstract] [Full Text] [Related]
27. Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease.
Bannai E; Yamashita H; Kaneko S; Ueda Y; Ozaki T; Tsuchiya H; Takahashi Y; Kaneko H; Kano T; Mimori A
Mod Rheumatol; 2016; 26(2):297-301. PubMed ID: 24697199
[TBL] [Abstract][Full Text] [Related]
28. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial.
Kaneko Y; Kameda H; Ikeda K; Ishii T; Murakami K; Takamatsu H; Tanaka Y; Abe T; Takeuchi T
Ann Rheum Dis; 2018 Dec; 77(12):1720-1729. PubMed ID: 30279267
[TBL] [Abstract][Full Text] [Related]
29. Antiproteinase 3 antibody in adult-onset Still's disease.
Al Attia HM
Clin Exp Rheumatol; 2006; 24(1):109-10. PubMed ID: 16539829
[No Abstract] [Full Text] [Related]
30. Treatment of refractory adult onset Still's disease with tocilizumab-a single centre experience and literature review.
Reihl Crnogaj M; Čubelić D; Babić A; Mayer M; Anić B
Rheumatol Int; 2020 Aug; 40(8):1317-1325. PubMed ID: 32506202
[TBL] [Abstract][Full Text] [Related]
31. Blockade of interleukin 1 receptor in Still's disease affects activation of peripheral T-lymphocytes.
Youssef J; Lazaro E; Blanco P; Viallard JF
J Rheumatol; 2008 Dec; 35(12):2453-6. PubMed ID: 19143047
[No Abstract] [Full Text] [Related]
32. [Adult refractory Still disease with atypical articular manifestations: efficacity of interleukin-6 antagonists (tocilizumab)].
Rkiouak A; Ennibi K; Zinebi A; Akhouad Y; Reggad A; Rabhi M; Chaari J
Ann Pharm Fr; 2012 May; 70(3):163-8. PubMed ID: 22655584
[TBL] [Abstract][Full Text] [Related]
33. Long-term safety of tocilizumab treatment on chronic active hepatitis C in a patient with adult onset Still's disease.
Forestier E; Pasquali JL
Joint Bone Spine; 2015 Mar; 82(2):136-7. PubMed ID: 25553837
[No Abstract] [Full Text] [Related]
34. A SEVERE CASE OF ADULT ONSET STILLS DISEASE WITH MYOPERICARDITIS, RESISTANT TO TREATMENT WITH TOCILIZUMAB BUT RESPONSIVE TO ANAKINRA.
Waghmare S; Valecka B; Cairns AP
Ulster Med J; 2015 May; 84(2):130-2. PubMed ID: 26376493
[No Abstract] [Full Text] [Related]
35. [Adult onset Still's disease].
Carreño Pérez L; López Longo FJ
Med Clin (Barc); 2007 Jul; 129(7):255-7. PubMed ID: 17683707
[No Abstract] [Full Text] [Related]
36. Successful treatment of refractory adult-onset Still's disease with anti-CD20 monoclonal antibody.
Bartoloni E; Alunno A; Luccioli F; Santoboni G; Gerli R
Clin Exp Rheumatol; 2009; 27(5):888-9. PubMed ID: 19917180
[No Abstract] [Full Text] [Related]
37. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still's disease: A meta-analysis.
Ma Y; Wu M; Zhang X; Xia Q; Yang J; Xu S; Pan F
Mod Rheumatol; 2018 Sep; 28(5):849-857. PubMed ID: 29251027
[TBL] [Abstract][Full Text] [Related]
38. [Biological treatment of rare inflammatory rheumatic diseases].
Baslund B
Ugeskr Laeger; 2008 Jun; 170(24):2150-2. PubMed ID: 18565301
[TBL] [Abstract][Full Text] [Related]
39. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis.
Kishida D; Okuda Y; Onishi M; Takebayashi M; Matoba K; Jouyama K; Yamada A; Sawada N; Mokuda S; Takasugi K
Mod Rheumatol; 2011 Apr; 21(2):215-8. PubMed ID: 20931272
[TBL] [Abstract][Full Text] [Related]
40. Reversal of severe hepatitis with infliximab in adult-onset Still's disease.
Singh B; Biboa J; Musuku S; Patel C; Pugh JL; Boyer TD
Am J Med; 2013 Feb; 126(2):e3-4. PubMed ID: 23331455
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
